Continuous Infusion or Intravenous Bolus: What Is the Rationale for Doxorubicin Administration?

Keywords

Continuous infusion, Medicine, Doxorubicin, Bolus (digestion), Daunorubicin

References

• Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer富夫 井田 — 1982
• Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomas.Gonzalo Caballero, Robert K. Ausman, Edward J. Quebbeman — 1985
• Comparative survival in tissue culture of normal and neoplastic human cells exposed to adriamycin.Charles M. Haskell, Ann Sullivan — 1974
• Continuous infusion chemotherapy: a critical review.N. J. Vogelzang — 1984
• The importance of dose intensity in chemotherapy of metastatic breast cancer.W M Hryniuk, Helen A. Bush — 1984
• Daunomycin administered by continuous intravenous infusion is effective in the treatment of acute nonlymphocytic leukaemiaJerry P. Lewis, Frederick J. Meyers, Leora Tanaka — 1985
• Effective treatment of advanced multiple myeloma refractory to alkylating agents.Bart Barlogie, Lon Smith, Raymond Alexanian — 1984
• Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.Sewa S. Legha, Robert S. Benjamin, Bruce R. MacKay — 1982
• Progress in the treatment of adults with acute leukemia: review of regimens containing cytarabine studied by the Southwest Oncology Group.Gerald P. Bodey — 1976
• Doxorubicin/vinblastine and doxorubicin/cyclophosphamide combination chemotherapy by continuous infusionJacob J. Lokich, T Zipoli, Cherie Moore — 1986
• Effect of adriamycin on CFUGM at plasma concentrations found following therapeutic infusions.R Bailey-Wood, C M Dallimore, J. A. Whittaker — 1984
• Optimal schedule for anthracyclines.Ian E. Smith — 1985
• Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response.Jacques Robert, Athanassions Illiadis, B Hœrni — 1982
• Concentration and time‐dependent inter‐relationships for antitumour drug cytotoxicities against tumour cells in vitroH. Thomas Rupniak, Richard D. H. Whelan, Bridget T. Hill — 1983
• Adriamycin chemotherapy—efficacy, safety, and pharmacologic basis of an intermittent single high‐dosage scheduleRobert S. Benjamin, Peter H. Wiernik, Nicholas R. Bachur — 1974
• The delivery of cancer chemotherapy by constant venous infusion ambulatory management of venous access and portable pumpJacob J. Lokich, Albert Bothe, N. Fine — 1982
• Continuous infusion or bolus injection in cancer chemotherapy.Robert W. Carlson, BRANIMIR IVAN SIKIC — 1983
• Dependence of the cytostatic effect of adriamycin on drug concenration and exposure time in vitro.H. Eichholtz-Wirth — 1980
• Cellular pharmacokinetics of doxorubicin in cultured mouse sarcoma cells originating from autochthonous tumors.Tan Nguyen-Ngoc, Patricia Vrignaud, Jacques Robert — 1984
• Implantable central venous access system.Albert Bothe, William Piccione, John J. Ambrosino — 1984

Cited by

• Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancerRafael Gumucio Rivas — 1991
• Epirubicin as a single agent therapy for the treatment of breast cancer — A pharmacokinetic and clinical studyStaffan Eksborg, Lennart Hardell, Nils‐Olof Bengtsson — 1992
• Investigation of the enterohepatic recirculation of Adriamycin and its metabolites by a linked-rat modelKamelia Behnia, Mehdi Boroujerdi — 1998
• Individual dose adaptation of anticancer drugs.B Desoize, Jacques Robert — 1994
• Does anthracycline administration by infusion in children affect late cardiotoxicity?Gill Levitt, I Dørup, K. Sørensen — 2004
• Doxorubicin weekly low dose administration: in vitro cytotoxicity generated by the typical pharmacokinetic profile.G. Milano, E. Cassuto‐Viguier, Jean–Louis Fischel — 1992
• A sensitive procedure for the quantitation of free and N-(2-hydroxypropyl) methacrylamide polymer-bound doxorubicin (PK1) and some of its metabolites, 13-dihydrodoxorubicin, 13-dihydrodoxorubicinone and doxorubicinone, in human plasma and urine by reversed-phase HPLC with fluorimetric detection.Daniela Fraier, E. Frigerio, E. Pianezzola — 1995
• Clinical and pharmacokinetic study of 96-h infusions of doxorubicin in advanced cancer patients.R. Bugat, Jacques Robert, A Herrera — 1989
• The pharmacokinetics of polymer-bound adriamycin.Len W. Seymour, Karel Ulbrich, J. Strohalm — 1990
• Mechanisms for anthracycline-induced cardiomyopathy: clinical and laboratory correlationsRobert J. Boucek — 1997
• Use of pharmacokinetic-pharmacodynamic relationships in the development of new anthracyclinesJacques Robert — 2004
• Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties?Stefan Bielack, R. Erttmann, Beate Kempf‐Bielack — 1996
• A precise pharmacodynamic study showing the advantage of a marked reduction in cardiotoxicity in continuous infusion of doxorubicinTaizo Ishisaka, Shinji Kishi, Kiyotaka Okura — 2006
• Limited sampling models for doxorubicin pharmacokinetics.Mark J. Ratain, Jacques Robert, W J van der Vijgh — 1991
• Chitosan-coated doxorubicin nano-particles drug delivery system inhibits cell growth of liver cancer via p53/PRC1 pathway.Bailiang Ye, Ru Zheng, Xiaojiao Ruan — 2018
• Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedureChristian Siebel, Gudrun Würthwein, Claudia Lanvers‐Kaminsky — 2019
• CARDIOPROTECTIONGill Levitt — 1999
• Treatment of Obesity Through Glial Cell-Derived Neurotrophic Factor Lipid Nanoparticle Delivery in MiceChunhua Yang, Simon M. Mwangi, Arun Balasubramaniam — 2023
• Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedureChristian Siebel, Gudrun Würthwein, Claudia Lanvers‐Kaminsky — 2019
• Additional file 1 of Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedureSiebel, Christian, Würthwein, Gudrun, Lanvers-Kaminsky, Claudia — 2020

Related papers

• Pharmacokinetics of vindesine given as an intravenous bolus and 24-hour infusion in humans.Takao Ohnuma, Larry Norton, Alicja Andrejczuk — 1985
• Dexmedetomidine as a Rapid Bolus for Treatment and Prophylactic Prevention of Emergence Agitation in Anesthetized ChildrenJohn A. Hauber, Peter J. Davis, Laima P. Bendel — 2016
• Comparison of continuous and intermittent bolus infusions of metoclopramide during 5-day continuous intravenous infusion with cisplatin.Kiyoshi Mori, Yoshikuni Saitou, Keigo Tominaga — 1991
• COMPARISON OF CARDIOPULMONARY RESPONSES TO DETOMIDINE ADMINISTERED AS AN INTRAVENOUS STEADY-STATE INFUSION VS INTRAVENOUS BOLUS IN STANDING HORSESCI. Dunlop, DA. Daunt, A Wagner — 1991
• Propofol: bolus or continuous infusionG.S. Brownlie, J. A. Baker, T. W. OGG — 1991
• Comparison of 5-fluorouracil anabolite levels after intravenous bolus and continuous infusionTheodore A. Stein, Beverly Bailey, Gerard P. Burns — 2004
• Comparison of 5-fluorouracil anabolite levels after intravenous bolus and continuous infusionBeverly Bailey, Gerard P. Burns, Theodore A. Stein — 1994
• Factor Vill level given by continuous infusion compared to by bolus in children with hemophilia A undergoing circumcision (case series)Ridwan Sugiarto T Ridwan Sugiarto — 2015
• Bolus versus continuous infusion of microbubble contrast agent for liver US: initial experience.Masahiro Okada, Christian W. Hoffmann, Karl J. Wolf — 2005